Press releases

Stockholm, September 12, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces it has signed an exclusive license and supply agreement with SCBIO Inc., a Korean pharmaceutical company for the commercialization of Oncopeptides’ flagship drug Pepaxti in South Korea

Stockholm – August 14, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the second quarter 2024

Stockholm – August 8, 2024 – Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, will publish the report for the second quarter of 2024, at 08:00 CET on August 14, 2024

Stockholm, July 22, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces entry of the first patient in a new study evaluating the real-world effectiveness and safety of Pepaxti in German patients. The study, which will include 100 patients across around 50 sites in Germany, aims at gathering evidence on Pepaxti’s effectiveness and safety in a real-world clinical practice and is the first Pepaxti study engaging treating physicians at multiple German sites

STOCKHOLM – June 28, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of votes in Oncopeptides has changed as a result of a conversion of 238,107 class C shares in Oncopeptides to a total 238,107 ordinary shares, in order to deliver ordinary shares to participants in Oncopeptides’ incentive program Board SHP 2023

Stockholm, June 27, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the first candidate drug based on the company´s unique platform for Small Polypeptide based innate Killer Engagers (SPiKE) has been selected

Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) was held on Friday, 31 May 2024. At the Annual General Meeting, the following principal resolutions were passed

Stockholm – May 31, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed as a result of the rights issue which ended on 3 May 2024

Oncopeptides AB (publ) (“Oncopeptides”) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the company has resolved on an issue of warrants in order to fulfil Oncopeptides obligations under the existing loan agreement with the European Investment Bank (the “EIB”)

Stockholm – May 30, 2024 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today publishes the report for the first quarter 2024